EML4 and cancer: While our data suggested several pan-cancer genomic gains/amplifications specific to patients with RBness patients (CCND1, BCL11A, EML4, XPO1, ALK, MSH2, and GPC3), none were a selective gene dependency in cancer cell lines, suggesting a potentially redundant contribution in driving RBness.